Wang Q, Redovan C, Tubbs R, Olencki T, Klein E, Kudoh S, Finke J, Bukowski R M
Department of Immunology, Cleveland Clinic Foundation, OH 44195, USA.
Int J Cancer. 1995 Jun 9;61(6):780-5. doi: 10.1002/ijc.2910610607.
The progression of tumors such as renal cell carcinoma (RCC), despite the presence of substantial lymphocytic infiltrates (TIL), suggests that the ability of the local immune response to control tumor growth is impaired. Cytokine gene expression was examined to further investigate the nature of this response. Initial studies were performed with frozen tumors using PCR-assisted mRNA amplification with cytokine-specific primers for interleukin 10 (IL-10), interleukin 2 (IL-2) and interferon-gamma (IFN-gamma). IL-2 mRNA was not detected, despite the presence of T cells as defined by the expression of CD3 gamma mRNA. In contrast, mRNA for IFN-gamma was expressed in 4/9 and for IL-10 in 5/9 tumors. To confirm this, 5 fresh tumor specimens were examined, and PCR demonstrated that IL-10 mRNA was detectable in 4/5 tumors from which RNA was isolated at the time of nephrectomy. In these experiments multiple cycles and dilutions were employed to semi-quantitate the expression of IL-10. To identify potential sources of this cytokine in the tumor bed, IL-10 mRNA expression in freshly isolated lymphocytes and tumor cells, TIL lines, cultured RCC and established RCC lines was examined. Our studies demonstrate that within the tumor TIL may be one source of IL-10. Lymphocyte-enriched populations from 4/5 tumors expressed IL-10 mRNA as did 4/6 freshly isolated tumor cell preparations. IL-10 gene expression was not detected, however, in tumor cells after one passage in vitro in short-term cultured RCC tumor cells (passages 2-5) or in established RCC tumor cell lines. Finally, 4/9 CD4+ and 2/5 CD8+ TIL lines expressed IL-10 mRNA either constitutively or after stimulation with anti-CD3 antibody. This finding was associated with IL-10 production in vitro. Our studies demonstrate that IL-10 mRNA is frequently present in RCC tumors and may originate from the tumor-infiltrating mononuclear cell population.
诸如肾细胞癌(RCC)等肿瘤的进展,尽管存在大量淋巴细胞浸润(TIL),这表明局部免疫反应控制肿瘤生长的能力受损。对细胞因子基因表达进行检测,以进一步研究这种反应的本质。最初的研究使用冷冻肿瘤,采用PCR辅助的mRNA扩增技术,使用针对白细胞介素10(IL-10)、白细胞介素2(IL-2)和干扰素-γ(IFN-γ)的细胞因子特异性引物。尽管存在由CD3γ mRNA表达所定义的T细胞,但未检测到IL-2 mRNA。相比之下,IFN-γ的mRNA在4/9的肿瘤中表达,IL-10的mRNA在5/9的肿瘤中表达。为了证实这一点,对5份新鲜肿瘤标本进行了检测,PCR结果显示,在肾切除时分离出RNA的4/5肿瘤中可检测到IL-10 mRNA。在这些实验中,采用了多个循环和稀释步骤来半定量IL-10的表达。为了确定肿瘤床中这种细胞因子的潜在来源,检测了新鲜分离的淋巴细胞和肿瘤细胞、TIL系、培养的RCC和已建立的RCC系中IL-10 mRNA的表达。我们的研究表明,在肿瘤内TIL可能是IL-10的一个来源。来自4/5肿瘤的富含淋巴细胞群体表达IL-10 mRNA,4/6新鲜分离的肿瘤细胞制剂也表达。然而,在短期培养的RCC肿瘤细胞(传代2 - 5)中传代一次后的肿瘤细胞或已建立的RCC肿瘤细胞系中未检测到IL-10基因表达。最后,4/9的CD4 +和2/5的CD8 + TIL系组成性地或在用抗CD3抗体刺激后表达IL-10 mRNA。这一发现与体外IL-10的产生相关。我们的研究表明,IL-10 mRNA经常存在于RCC肿瘤中,并且可能起源于肿瘤浸润的单核细胞群体。